Clinical Trial Update: A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating Stempeucel for critical limb ischemia due to Buerger's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Thromboangiitis Obliterans

Drugs mentioned

• Stempeucel (mesenchymal stromal cells)

Snippet

Sponsor: Stempeutics Research Pvt Ltd | Conditions: Critical Limb Ischemia Due to Buerger's Disease | Phase 2 | Status: WITHDRAWN